For example, testing ratesvaries among cancer types, with higher rates observed for primarilyBRCA1/2-related cancers (26.0% for breast, 38.6% for ovarian)compared to Lynch syndrome-associated types (5.6% for colorectal, 6.4% for endometrial).Despite similar pathogenic frequencies in Lynch syndrome and BRCA1/2genes, under-testing persisted in Lynch syndrome-linked cancers. Here, BRCA1 is linked to Lynch syndrome.